Acta Pharm Sin B 11:23962415 Sumida Y, Yoneda M (2018) Current and future pharmacological therapies for NAFLD/NASH
Beyond cognitive deficits, PD patients frequently experience neuropsychiatric symptoms such as depression and anxiety, which result from widespread neurotransmitter dysregulation, including alterations in serotonin and norepinephrine levels
Frster L, Indra D, Rosenberger K, Zver L, Hofbauer R
Precision-Crafted Quality
J Cell Physiol (2020) 235(2):97992
Author: Eric Patterson, LPC (No change) Medical Reviewer: Benjamin Troy, MD (No change) Primary Changes: Added summary block and star rating breakdown Author: Eric Patterson, LPC Medical Reviewer: Benjamin Troy, MD Your Voice Matters Leave your own reviews